Efficacy of the new infliximab biosimilar CT-P13 induction therapy in @entity30 and XXXX - experiences from a single center.

@entity1 @entity31 @entity30
BACKGROUND: CT-P13 is the first biosimilar monoclonal antibody to infliximab (IFX); it has been approved for the same indications as its IFX counterpart in Hungary. The aim of this study was to assess the efficacy of CT-P13 induction therapy in @entity1 with @entity30 ( @entity30 ) and @entity31 ( @entity31 ). METHODS: @entity1 diagnosed with @entity30 and @entity31 , who were administered CT-P13, were prospectively enrolled. Disease activity was estimated at the start and after the induction therapy. In @entity1 with @entity31 , sigmoideoscopy was also performed at the end of the induction therapy. RESULTS: Eighteen @entity30 and 21 @entity31 @entity1 were enrolled. Induction treatment was completed in 16 of the @entity30 and 15 of the @entity31 @entity1 . In those with luminal @entity30 , clinical response and remission was achieved in 6 (37.5%) and 8 (50%) of the @entity1 at Week 8. In @entity31 , clinical response and remission was achieved in 3 (20%) and 10 (66.7%) @entity1 at Week 8. Mucosal healing was shown in 11 @entity1 . CONCLUSIONS: This was the first study to prospectively evaluate the outcome of CT-P13 induction therapy in @entity30 and @entity31 . Our results confirm that induction with CT-P13 is safe and effective.
